AU Stock MarketDetailed Quotes

ZLDDG Zelira Therapeutics Ltd

Watchlist
  • 0.000
  • 0.0000.00%
20min DelayMarket Closed Dec 31 10:00 AET
0Market Cap0.00P/E (Static)

Zelira Therapeutics Ltd Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Jun 30, 2021
(FY)Jun 30, 2020
(FY)Jun 30, 2019
Operating cash flow (direct method)
Cash income from operating activities
71.47%-1.01M
-61.84%-3.53M
-2.18M
Revenue from customers
--621.22K
----
----
Other cash income from operating activities
53.85%-1.63M
-61.84%-3.53M
---2.18M
Cash paid
-122.25%-7.61M
-171.21%-3.42M
-1.26M
Payments to suppliers for goods and services
-122.25%-7.61M
-171.21%-3.42M
---1.26M
Direct interest received
-94.76%723
-85.75%13.79K
--96.77K
Operating cash flow
-24.23%-8.62M
-107.41%-6.94M
---3.34M
Investing cash flow
Cash flow from continuing investing activities
24.56%1.38M
51.25%1.11M
731.62K
Capital expenditure reported
33.59%1.38M
34.17%1.03M
--769.03K
Net PPE purchase and sale
----
43.43%-15.97K
---28.23K
Net business purchase and sale
----
--189.78K
----
Net other investing changes
----
-978.70%-99.04K
---9.18K
Cash from discontinued investing activities
Investing cash flow
24.56%1.38M
51.25%1.11M
--731.62K
Financing cash flow
Cash flow from continuing financing activities
133.91%10.53M
4.5M
Net common stock issuance
133.91%10.53M
--4.5M
----
Cash from discontinued financing activities
Financing cash flow
133.91%10.53M
--4.5M
----
Net cash flow
Beginning cash position
-44.78%1.7M
-45.95%3.07M
--5.69M
Current changes in cash
348.08%3.29M
49.19%-1.33M
---2.61M
Effect of exchange rate changes
60.97%-19K
---48.67K
----
End cash Position
192.93%4.97M
-44.78%1.7M
--3.07M
Free cash from
-24.23%-8.62M
-107.41%-6.94M
---3.34M
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
(FY)Jun 30, 2021(FY)Jun 30, 2020(FY)Jun 30, 2019
Operating cash flow (direct method)
Cash income from operating activities 71.47%-1.01M-61.84%-3.53M-2.18M
Revenue from customers --621.22K--------
Other cash income from operating activities 53.85%-1.63M-61.84%-3.53M---2.18M
Cash paid -122.25%-7.61M-171.21%-3.42M-1.26M
Payments to suppliers for goods and services -122.25%-7.61M-171.21%-3.42M---1.26M
Direct interest received -94.76%723-85.75%13.79K--96.77K
Operating cash flow -24.23%-8.62M-107.41%-6.94M---3.34M
Investing cash flow
Cash flow from continuing investing activities 24.56%1.38M51.25%1.11M731.62K
Capital expenditure reported 33.59%1.38M34.17%1.03M--769.03K
Net PPE purchase and sale ----43.43%-15.97K---28.23K
Net business purchase and sale ------189.78K----
Net other investing changes -----978.70%-99.04K---9.18K
Cash from discontinued investing activities
Investing cash flow 24.56%1.38M51.25%1.11M--731.62K
Financing cash flow
Cash flow from continuing financing activities 133.91%10.53M4.5M
Net common stock issuance 133.91%10.53M--4.5M----
Cash from discontinued financing activities
Financing cash flow 133.91%10.53M--4.5M----
Net cash flow
Beginning cash position -44.78%1.7M-45.95%3.07M--5.69M
Current changes in cash 348.08%3.29M49.19%-1.33M---2.61M
Effect of exchange rate changes 60.97%-19K---48.67K----
End cash Position 192.93%4.97M-44.78%1.7M--3.07M
Free cash from -24.23%-8.62M-107.41%-6.94M---3.34M
Accounting Standards US-GAAPUS-GAAPUS-GAAP